BCG: a vaccine with multiple faces

References

• Luca S, Mihaescu T. History of BCG vaccine. Maedica (Buchar). 2013;8:53–58.
   PubMedGoogle Scholar
• Benévolo-de-Andrade TC, Monteiro-Maia R, Cosgrove C, Castello-Branco LR. BCG Moreau Rio de Janeiro: an oral vaccine against tuberculosis-review. Mem Inst Oswaldo Cruz. 2005;100:459–65. doi:10.1590/S0074-02762005000500002.
   PubMed Web of Science ®Google Scholar
• Dagg B, Hockley J, Rigsby P, Ho MM. The establishment of sub-strain specific WHO reference reagents for BCG vaccine. Vaccine. 2014;32:6390–95. doi:10.1016/j.vaccine.2014.09.065.
   PubMed Web of Science ®Google Scholar
• Comstock GW. The International tuberculosis campaign: a pioneering venture in mass vaccination and research. Clin Infect Dis. 1994;19:528–40. doi:10.1093/clinids/19.3.528.
   PubMed Web of Science ®Google Scholar
• Boman G. The ongoing story of the Bacille Calmette-Guérin (BCG) vaccination. Acta Paediatr. 2016;105:1417–20. doi:10.1111/apa.13585.
   PubMed Web of Science ®Google Scholar
• Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. The BCG world atlas: a database of global BCG vaccination policies and practices. PLoS Med. 2011. doi:10.1371/journal.pmed.1001012.
   PubMed Web of Science ®Google Scholar
• Butkeviciute E, Jones CE, Smith SG. Heterologous effects of infant BCG vaccination: potential mechanisms of immunity. Future Microbiol. 2018;13:1193–208. Epub 2018 Aug 17. doi:10.2217/fmb-2018-0026.
   PubMed Web of Science ®Google Scholar
• Kowalewicz-Kulbat M, Locht C. BCG and protection against inflammatory and auto-immune diseases. Expert Rev Vaccines. 2017;16:1–10. Epub 2017 May 30. doi:10.1080/14760584.2017.1333906.
   PubMed Web of Science ®Google Scholar
• Shann F. Nonspecific effects of vaccines and the reduction of mortality in children. Clin Ther. 2013;35:109–14. doi:10.1016/j.clinthera.2013.01.007.
   PubMed Web of Science ®Google Scholar
• Blok BA, Arts RJ, van Crevel R, Benn CS, Netea MG. Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines. J Leukoc Biol. 2015;98:347–56. doi:10.1189/jlb.5RI0315-096R.
   PubMed Web of Science ®Google Scholar
• Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet. 2006;367:1173–80. doi:10.1016/S0140-6736(06)68507-3.
   PubMed Web of Science ®Google Scholar
• Awasthi S, Moin S. Effectiveness of BCG vaccination against tuberculous meningitis. Indian Pediatr. 1999;36:455–60.
   PubMedGoogle Scholar
• Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA. 1994;271:698–702. doi:10.1001/jama.1994.03510330076038.
   PubMed Web of Science ®Google Scholar
• Sutherland I, Lindgren I. The protective effect of BCG vaccination as indicated by autopsy studies. Tubercle. 1979;60:225–31. doi:10.1016/0041-3879(79)90003-5.
   PubMedGoogle Scholar
• Soysal A, Millington KA, Bakir M, Dosanjh D, Aslan Y, Deeks JJ, Efe S, Staveley I, Ewer K, Lalvani A. Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study. Lancet. 2005;366:1443–51. doi:10.1016/S0140-6736(05)67534-4.
   PubMed Web of Science ®Google Scholar
• Eriksen J, Chow JY, Mellis V, Whipp B, Walters S, Abrahamson E, Abubakar I. Protective effect of BCG vaccination in a nursery outbreak in 2009: time to reconsider the vaccination threshold? Thorax. 2010;65:1067–71. Epub 2010 Oct 28. doi:10.1136/thx.2010.140186.
   PubMed Web of Science ®Google Scholar
• Faurholt-Jepsen D, Range N, Praygod G, Jeremiah K, Faurholt-Jepsen M, Aabye MG, Grewal HM, Changalucha J, Witte DR, Andersen AB, et al. BCG protects against tuberculosis irrespective of HIV status: a matched case-control study in Mwanza, Tanzania. Thorax. 2013;68:288–89. doi:10.1136/thoraxjnl-2012-201971.
   PubMed Web of Science ®Google Scholar
• Jeremiah K, Praygod G, Faurholt-Jepsen D, Range N, Andersen AB, Grewal HM, Friis H. BCG vaccination status may predict sputum conversion in patients with pulmonary tuberculosis: a new consideration for an old vaccine? Thorax. 2010;65:1072–76. doi:10.1136/thx.2010.134767.
   PubMed Web of Science ®Google Scholar
• Eisenhut M, Paranjothy S, Abubakar I, Bracebridge S, Lilley M, Mulla R, Lack K, Chalkley D, McEvoy M. BCG vaccination reduces risk of infection with Mycobacterium tuberculosis as detected by gamma interferon release assay. Vaccine. 2009;27:6116–20. doi:10.1016/j.vaccine.2009.08.031.
   PubMed Web of Science ®Google Scholar
• Gomes RR, Antunes DE, Dos Santos DF, Sabino EFP, Oliveira DB, Goulart IMB. BCG vaccine and leprosy household contacts: protective effect and probability to becoming sick during follow-up. Vaccine. 2019;37:6510–17. Epub 2019 Sep 6. doi:10.1016/j.vaccine.2019.08.067.
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Finn A, Curtis N. Does BCG vaccination protect against nontuberculous mycobacterial infection? A systematic review and meta-analysis. J Infect Dis. 2018;218:679–87. doi:10.1093/infdis/jiy207.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Soares-Weiser K, López-López JA, Kakourou A, Chaplin K, Christensen H, Martin NK, Sterne JA, Reingold AL. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ. 2016;355:i5170. doi:10.1136/bmj.i5170.
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Curtis N. The influence of BCG on vaccine responses - a systematic review. Expert Rev Vaccines. 2018;17:547–54. doi:10.1080/14760584.2018.1483727.
   PubMed Web of Science ®Google Scholar
• Freyne B, Marchant A, Curtis N. BCG-associated heterologous immunity, a historical perspective: intervention studies in animal models of infectious diseases. Trans R Soc Trop Med Hyg. 2015;109:52–61. doi:10.1093/trstmh/trv021.
   PubMed Web of Science ®Google Scholar
• Nankabirwa V, Tumwine JK, Mugaba PM, Tylleskär T, Sommerfelt H. PROMISE- EBF study group. Child survival and BCG vaccination: a community based prospective cohort study in Uganda. BMC Public Health. 2015;15:175. doi:10.1186/s12889-015-1497-8.
   PubMed Web of Science ®Google Scholar
• Holm-Delgado MG, Stuart EA, Black RE. Acute lower respiratory infection among Bacille Calmette-Guérin (BCG)-vaccinated children. Pediatrics. 2014;133(1):e73–81. Epub 2013 Dec 30. doi:10.1542/peds.2013-2218.
   PubMed Web of Science ®Google Scholar
• Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. BMJ. 2000;321:1435–38.
   PubMed Web of Science ®Google Scholar
• Eisenhut M. Enhanced innate immunity as explanation for reduced Mycobacterium tuberculosis infection in Bacillus Calmette-Guérin-immunized children. Am J Respir Crit Care Med. 2013;188:257–58. doi:10.1164/rccm.201301-0060LE.
   PubMed Web of Science ®Google Scholar
• Lalvani A, Sridhar S. BCG vaccination: 90 years on and still so much to learn. Thorax. 2010;65:1036–38. doi:10.1136/thx.2010.140996.
   PubMed Web of Science ®Google Scholar
• Stensballe LG, Sørup S, Aaby P, Benn CS, Greisen G, Jeppesen DL, Birk NM, Kjærgaard J, Nissen TN, Pihl GT, et al. BCG vaccination at birth and early childhood hospitalisation: a randomised clinical multicentre trial. Arch Dis Child. 2017;102:224–31. doi:10.1136/archdischild-2016-310760.
   PubMed Web of Science ®Google Scholar
• Post CL, Victora CG, Valente JG, Leal Mdo C, Niobey FM, Sabroza PC. Prognostic factors of hospital mortality from diarrhea or pneumonia in infants younger than 1 year old. A case-control study. Rev Saude Publica. 1992;26:369–78. Article in Portuguese. doi:10.1590/S0034-89101992000600001.
   PubMed Web of Science ®Google Scholar
• Kleinnijenhuis J, van Crevel R, Netea MG. Trained immunity: consequences for the heterologous effects of BCG vaccination. Trans R Soc Trop Med Hyg. 2015;109:29–35. doi:10.1093/trstmh/tru168.
   PubMed Web of Science ®Google Scholar
• Kleinnijenhuis J, Quintin J, Preijers F, Joosten LA, Jacobs C, Xavier RJ, van der Meer JW, van Crevel R, Netea MG. BCG-induced trained immunity in NK cells: role for non-specific protection to infection. Clin Immunol. 2014;155:213–19. doi:10.1016/j.clim.2014.10.005.
   PubMed Web of Science ®Google Scholar
• Moorlag SJCFM, Arts RJW, van Crevel R, Netea MG. Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect. 2019 May 2. pii: S1198–743X(19)30197–1. Epub ahead of print. doi:10.1016/j.cmi.2019.04.020.
   PubMed Web of Science ®Google Scholar
• Dos Santos JC, Vilela Teodoro Silva M, Ribeiro-Dias F, Joosten LAB. Non-specific effects of BCG in protozoal infections: tegumentary leishmaniasis and malaria. Clin Microbiol Infect. 2019 Jun 15. pii: S1198–743X(19)30292–7. Epub ahead of print. doi:10.1016/j.cmi.2019.06.002.
   PubMed Web of Science ®Google Scholar
• Mawa PA, Webb EL, Filali-Mouhim A, Nkurunungi G, Sekaly RP, Lule SA, Prentice S, Nash S, Dockrell HM, Elliott AM, et al. Maternal BCG scar is associated with increased infant proinflammatory immune responses. Vaccine. 2017;35:273–82. doi:10.1016/j.vaccine.2016.11.079.
   PubMed Web of Science ®Google Scholar
• Ovchinnikova OA, Berge N, Kang C, Urien C, Ketelhuth DF, Pottier J, Drouet L, Hansson GH, Marchal G, Back M, et al. Mycobacterium bovis BCG killed by extended freeze-drying induces an immunoregulatory profile and protects against atherosclerosis. J Intern Med. 2014;275:49–58. doi:10.1111/joim.12127.
   PubMed Web of Science ®Google Scholar
• Lamb DJ, Eales LJ, Ferns GA. Immunization with bacillus Calmette-Guerin vaccine increases aortic atherosclerosis in the cholesterol-fed rabbit. Atherosclerosis. 1999;143:105–13. doi:10.1016/S0021-9150(98)00284-6.
   PubMed Web of Science ®Google Scholar
• van Dam AD, Bekkering S, Crasborn M, van Beek L, van den Berg SM, Vrieling F, Joosten SA, Van Harmelen V, de Winther MPJ, Lutjohann D, et al. BCG lowers plasma cholesterol levels and delays atherosclerotic lesion progression in mice. Atherosclerosis. 2016;251:6–14. doi:10.1016/j.atherosclerosis.2016.05.031.
   PubMed Web of Science ®Google Scholar
• Kumral A, İşcan B, Tuzun F, Micili SC, Arslan MK, Tugyan K, Duman N, Ozkan H. Bacillus Calmette-Guerín vaccination: a novel therapeutic approach to preventing hyperoxic lung injury. J Matern Fetal Neonatal Med. 2015;28:1950–56. Epub 2015 Jan 14. doi:10.3109/14767058.2014.973396.
   PubMed Web of Science ®Google Scholar
• Weiss DW, Bonhag RS, Deome KB. Protective activity of fractions of tubercle bacilli against isologous tumours in mice. Nature. 1961;190:889–91. doi:10.1038/190889a0.
   PubMed Web of Science ®Google Scholar
• Bast RC Jr, Zbar B, Borsos T, Rapp HJ. BCG and cancer (first of two parts). N Engl J Med. 1974;290:1413–20. doi:10.1056/NEJM197406202902506.
   PubMed Web of Science ®Google Scholar
• Bast RC Jr., Zbar B, Borsos T, Rapp HJ. BCG and cancer. N Engl J Med. 1974;290:1458–69. doi:10.1056/NEJM197406272902605.
   PubMed Web of Science ®Google Scholar
• Davignon L, Robillard P, Lemonde P, Frappier A. B.C.G. vaccination and leukemia mortality. Lancet. 1970;2:638. doi:10.1016/S0140-6736(70)91402-9.
   PubMed Web of Science ®Google Scholar
• Morra ME, Kien ND, Elmaraezy A, Abdelaziz OAM, Elsayed AL, Halhouli O, Montas AM, Vu TL, Ho C, Foly AS, et al. Early vaccination protects against childhood leukemia: A systematic review and meta-analysis. Sci Rep. 2017;7:15986. doi:10.1038/s41598-017-16067-0.
   PubMed Web of Science ®Google Scholar
• Usher NT, Chang S, Howard RS, Martinez A, Harrison LH, Santosham M, Aronson NE. Association of BCG vaccination in childhood with subsequent cancer diagnoses: a 60-year follow-up of a clinical trial. JAMA Netw Open. 2019 Sep 4;2(9):e1912014. doi:10.1001/jamanetworkopen.2019.12014.
   PubMed Web of Science ®Google Scholar
• Kölmel KF, Grange JM, Krone B, Mastrangelo G, Rossi CR, Henz BM, Seebacher C, Botev IN, Niin N, Nambert D, et al. Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European organization for research and treatment of cancer cohort study on 542 patients. Eur J Cancer. 2005;41:118–25. doi:10.1016/j.ejca.2004.09.023.
   PubMed Web of Science ®Google Scholar
• Shehadeh N, Etzioni A, Cahana A, Teninboum G, Gorodetsky B, Barzilai D, Karnieli E. Repeated BCG vaccination is more effective than a single dose in preventing diabetes in non-obese diabetic (NOD) mice. Isr J Med Sci. 1997;33:711–15.
   PubMedGoogle Scholar
• Parent ME, Siemiatycki J, Menzies R, Fritschi L, Colle E. Bacille Calmette-Guérin vaccination and incidence of IDDM in Montreal, Canada. Diabetes Care. 1997;20:767–72. doi:10.2337/diacare.20.5.767.
   PubMed Web of Science ®Google Scholar
• Huppmann M, Baumgarten A, Ziegler AG, Bonifacio E. Neonatal bacille Calmette-Guerin vaccination and type 1 diabetes. Diabetes Care. 2005;28:1204–06. doi:10.2337/diacare.28.5.1204.
   PubMed Web of Science ®Google Scholar
• Zuo Z, Qi F, Yang J, Wang X, Wu Y, Wen Y, Yuan Q, Zou J, Guo K, Yao ZB. Immunization with bacillus Calmette-Guérin (BCG) alleviates neuroinflammation and cognitive deficits in APP/PS1 mice via the recruitment of inflammation-resolving monocytes to the brain. Neurobiol Dis. 2017;101:27–39. doi:10.1016/j.nbd.2017.02.001.
   PubMed Web of Science ®Google Scholar
• Gofrit ON, Bercovier H, Klein BY, Cohen IR, Ben-Hur T, Greenblatt CL. Can immunization with bacillus Calmette-Guérin (BCG) protect against Alzheimer’s disease? Med Hypotheses. 2019;123:95–97. doi:10.1016/j.mehy.2019.01.007.
   PubMed Web of Science ®Google Scholar
• Pereira SM, Dourado I, Barreto ML, Cunha SS, Ichiara MY, Hijjar MA, Goes JC, Rodrigues LC. Sensitivity and specificity of BCG scar reading in Brazil. Int J Tuberc Lung Dis. 2001;5:1067–70.
   PubMed Web of Science ®Google Scholar
• Lugosi L. Theoretical and methodological aspects of BCG vaccine from the discovery of Calmette and Guérin to molecular biology. A review. Tuber Lung Dis. 1992;73:252–61. doi:10.1016/0962-8479(92)90129-8.
   PubMedGoogle Scholar
• Shaaban MA, Abdul Ati M, Bahr GM, Standford JL, Lockwood DN, McManus IC. Revaccination with BCG: its effects on skin tests in Kuwaiti seior school children. Eur Respir J. 1990;3:187–91.
   PubMed Web of Science ®Google Scholar
• Fjällbrant H, Ridell M, Larsson LO. BCG scar and tuberculin reactivity in children and adults. Scand J Infect Dis. 2008;40:387–92. doi:10.1080/00365540701732905.
   PubMed Web of Science ®Google Scholar
• Timmermann CA, Biering-Sørensen S, Aaby P, Fisker AB, Monteiro I, Rodrigues A, Benn CS, Ravn H. Tuberculin reaction and BCG scar: association with infant mortality. Trop Med Int Health. 2015;20:1733–44. doi:10.1111/tmi.12614.
   PubMed Web of Science ®Google Scholar
• Garly ML, Martins CL, Balé C, Baldé MA, Hedegaard KL, Gustafson P, Lisse IM, Whittle HC, Aaby P. BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG? Vaccine. 2003;21:2782–90. doi:10.1016/S0264-410X(03)00181-6.
   PubMed Web of Science ®Google Scholar
• Roth A, Gustafson P, Nhaga A, Djana Q, Poulsen A, Garly ML, Jensen H, Sodemann M, Rodrigues A, Aaby P. BCG vaccination scar associated with better childhood survival in Guinea-Bissau. Int J Epidemiol. 2005;34:540–47. doi:10.1093/ije/dyh392.
   PubMed Web of Science ®Google Scholar
• Fine PE, Sterne JA, Pönnighaus JM, Rees RJ. Delayed-type hypersensitivity, mycobacterial vaccines and protective immunity. Lancet. 1994;344:1245–49. doi:10.1016/S0140-6736(94)90748-X.
   PubMed Web of Science ®Google Scholar
• Roth A, Sodemann M, Jensen H, Poulsen A, Gustafson P, Gomes J, Djana Q, Jakobsen M, Garly M-L, Rodrigues A, et al. Vaccination technique, PPD reaction and BCG scarring in a cohort of children born in Guinea-Bissau 2000–2002. Vaccine. 2005;23:3991–98. doi:10.1016/j.vaccine.2004.10.022.
   PubMed Web of Science ®Google Scholar
• Kawasaki T. Two cases with acute febrile mucocutaneous lymph node syndrome possibly induced by vaccinia or measles vaccination. Jpn J Pediatr. 1970;23:657–62.
   Google Scholar
• Gamez-Gonzalez LB, Hamada H, Llamas-Guillen BA, Ruiz-Fernandez M, Yamazaki-Nakashimada M. BCG and Kawasaki disease in Mexico and Japan. Hum Vaccin Immunother. 2017;13:1091–93. doi:10.1080/21645515.2016.1267083.
   PubMed Web of Science ®Google Scholar
• García Pavón S, Staines Boone T, Hernández Bautista V, Yamazaki Nakashimada MA. Reactivation of the scar of BCG vaccination in Kawasaki’s disease: clinical case and literature review. Rev Alerg Mex. 2006;53:76–78.
   PubMedGoogle Scholar
• Kakisaka Y, Ohara T, Katayama S, Suzuki T, Sasai S, Hino-Fukuyo N, Kure S. Human herpes virus type 6 can cause skin lesions at the BCG inoculation site similar to Kawasaki Disease. Tohoku J Exp Med. 2012;228:351–53. doi:10.1620/tjem.228.351.
   PubMed Web of Science ®Google Scholar
• Muthuvelu S, Lim KS, Huang LY, Chin ST, Mohan A. Measles infection causing bacillus Calmette-Guérin reactivation: a case report. BMC Pediatr. 2019 Jul 24;19(1):251. doi:10.1186/s12887-019-1635-z.
   PubMedGoogle Scholar
• Uehara R, Igarashi H, Yashiro M, Nakamura Y, Yanagawa H. Kawasaki disease patients with redness or crust formation at the bacille Calmette-Guérin inoculation site. Pediatr Infect Dis J. 2010;29:430–33. doi:10.1097/INF.0b013e3181cacede.
   PubMed Web of Science ®Google Scholar
• Garrido-García LM, Castillo-Moguel A, Vázquez-Rivera M, Cravioto P, Fernando G. Reaction of the BCG scar in the acute phase of Kawasaki Disease in Mexican children. Pediatr Infect Dis J. 2017;36:e237–e241. doi:10.1097/INF.0000000000001633.
   PubMed Web of Science ®Google Scholar
• Araki T, Kodera A, Kitada K, Fujiwara M, Muraoka M, Abe Y, Ikeda M, Tsukahara H. Analysis of factors associated with development of Bacille Calmette-Guérin inoculation site change in patients with Kawasaki disease. J Int Med Res. 2018;46:1640–48. doi:10.1177/0300060518760462.
   PubMed Web of Science ®Google Scholar
• Tseng HC, Ho JC, Guo MM, Lo MH, Hsieh KS, Tsai WC, Kuo HC, Lee CH. Bull’s eye dermatoscopy pattern at bacillus Calmette-Guérin inoculation site correlates with systemic involvements in patients with Kawasaki disease. J Dermatol. 2016;43:1044–50. doi:10.1111/1346-8138.13315.
   PubMed Web of Science ®Google Scholar
• Sato N, Sagawa K, Sasaguri Y, Inoue O, Kato H. Immunopathology and cytokine detection in the skin lesions of patients with Kawasaki disease. J Pediatr. 1993;122:198–203. doi:10.1016/S0022-3476(06)80113-7.
   PubMed Web of Science ®Google Scholar
• Kuniyuki S, Asada M. An ulcerated lesion at the BCG vaccination site during the course of Kawasaki disease. J Am Acad Dermatol. 1997;37(2 Pt 2):303–04. doi:10.1016/S0190-9622(97)80376-3.
   PubMed Web of Science ®Google Scholar
• Sireci G, Dieli F, Salerno AT. cells recognize an immunodominant epitope of heat shock protein 65 in Kawasakidisease. Mol Med. 2000;6:581–90. doi:10.1007/BF03401796.
   PubMed Web of Science ®Google Scholar
• Fujieda M, Karasawa R, Takasugi H, Yamamoto M, Kataoka K, Yudoh K, Kato T, Ozaki S, Wakiguchi H. A novel anti-peroxiredoxin autoantibody in patients with Kawasaki disease. Microbiol Immunol. 2012;56:56–61. doi:10.1111/j.1348-0421.2011.00393.x.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Yamamura J, Sato H, Kakinuma H, Takahashi H. Vasculitis induced by immunization with bacillus Calmette-Guérin followed by atypical mycobacterium antigen: a new mouse model for Kawasaki disease. FEMS Immunol Med Microbiol. 2007;49:391–97. doi:10.1111/j.1574-695X.2007.00217.x.
   PubMedGoogle Scholar
• Chun JK, Jeon BY, Kang DW, Kim DS. Bacille Calmette Guérin (BCG) can induce Kawasaki disease-like features in programmed death-1 (PD-1) gene knockout mice. Clin Exp Rheumatol. 2011;29:743–50.
   PubMed Web of Science ®Google Scholar
• Kadowaki J, Yamaguchi M, Sato S. Three cases suspected as acute febrile mucocutaneous lymph node syndrome: emphasis on the cutaneous changes at the BCG and tuberculin inoculated site in one case. Jpn J Pediatr. 1972;25:901–05.
   Google Scholar
• Hsu YH, Wang YH, Hsu WY, Lee YP. Kawasaki disease characterized by erythema and induration at the bacillus Calmette-Guérin and purified protein derivative inoculation sites. Pediatr Infect Dis J. 1987;6:576–78. doi:10.1097/00006454-198706000-00020.
   PubMed Web of Science ®Google Scholar
• Bertotto A, Spinozzi F, Vagliasindi C, Radicioni M, De Rosa O, Vaccaro R. Tuberculin skin test reactivity in Kawasaki disease. Pediatr Res. 1997;41:560–62. doi:10.1203/00006450-199704000-00017.
   PubMed Web of Science ®Google Scholar
• Kollmann TR, Klein EJ, Stefanelli CB, Marcuse EK. Purified protein derivative anergy in Kawasaki disease. Pediatr Infect Dis J. 2001;20:81–82. doi:10.1097/00006454-200101000-00018.
   PubMed Web of Science ®Google Scholar
• Chalmers D, Corban JG, Moore PP. BCG site inflammation: a useful diagnostic sign in incomplete Kawasaki disease. J Paediatr Child Health. 2008;44:525. doi:10.1111/j.1440-1754.2008.01364.x.
   PubMed Web of Science ®Google Scholar
• Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116:180–83. doi:10.1016/S0022-5347(17)58737-6.
   PubMed Web of Science ®Google Scholar
• Meyer JP, Persad R, Gillatt DA. Use of bacille Calmette-Guérin in superficial bladder cancer. Postgrad Med J. 2002;78:449–54. doi:10.1136/pmj.78.922.449.
   PubMed Web of Science ®Google Scholar
• Alexandroff AB, Jackson AM, O’Donnell MA, James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 1999;353:1689–94. doi:10.1016/S0140-6736(98)07422-4.
   PubMed Web of Science ®Google Scholar
• Redelman-Sidi G, Glickman MS, Bochner BH. The mechanism of action of BCG therapy for bladder cancer–a current perspective. Nat Rev Urol. 2014;11:153–62. doi:10.1038/nrurol.2014.15.
   PubMed Web of Science ®Google Scholar
• Lattime EC, Gomella LG, McCue PA. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res. 1992;52:4286–90.
   PubMed Web of Science ®Google Scholar
• de Boer EC, Somogyi L, de Ruiter GJ, de Reijke TM, Kurth KH, Schamhart DH. Role of interleukin-8 in onset of the immune response in intravesical BCG therapy for superficial bladder cancer. Urol Res. 1997;25:31–34. doi:10.1007/BF00941903.
   PubMedGoogle Scholar
• de Reijke TM, Vos PC, de Boer EC, Bevers RF, de Muinck Keizer WH, Kurth KH, Schamhart DH. Cytokine production by the human bladder carcinoma cell line T24 in the presence of bacillus Calmette-Guerin (BCG). Urol Res. 1993;21:349–52. doi:10.1007/BF00296835.
   PubMedGoogle Scholar
• Thanhäuser A, Böhle A, Flad HD, Ernst M, Mattern T, Ulmer AJ. Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cells against human bladder carcinoma cell lines in vitro. Cancer Immunol Immunother. 1993;37:105–11. doi:10.1007/BF01517042.
   PubMed Web of Science ®Google Scholar
• Ibarra C, Karlsson M, Codeluppi S, Varas-Godoy M, Zhang S, Louhivuori L, Mangsbo S, Hosseini A, Soltani N, Kaba R, et al. BCG-induced cytokine release in bladder cancer cells is regulated by Ca2+ signaling. Mol Oncol. 2018. doi:10.1002/1878-0261.12397.
   PubMed Web of Science ®Google Scholar
• Yang J, Jones MS, Ramos RI, Chan AA, Lee AF, Foshag LJ, Sieling PA, Faries MB, Lee DJ. Insights into local tumor microenvironment immune factors associated with regression of cutaneous melanoma metastases by Mycobacterium bovis bacille Calmette-Guérin. Front Oncol. 2017;7:61. doi:10.3389/fonc.2017.00061.
   PubMed Web of Science ®Google Scholar
• Shirakawa T, Enomoto T, Shimazu S, Hopkin JM. The inverse association between tuberculin responses and atopic disorder. Science. 1997;275(5296):77–79. doi:10.1126/science.275.5296.77.
   PubMed Web of Science ®Google Scholar
• Choi IS, Koh YI. Therapeutic effects of BCG vaccination in adult asthmatic patients: a randomized, controlled trial. Ann Allergy Asthma Immunol. 2002;88:584–91. doi:10.1016/S1081-1206(10)61890-X.
   PubMed Web of Science ®Google Scholar
• Yang J, Qi F, Yao Z. Neonatal bacillus Calmette-Guérin vaccination alleviates lipopolysaccharide-induced neurobehavioral impairments and neuroinflammation in adult mice. Mol Med Rep. 2016 Aug;14(2):1574–86. doi:10.3892/mmr.2016.5425.
   PubMed Web of Science ®Google Scholar
• Lee J, Reinke EK, Zozulya AL, Sandor M, Fabry Z. Mycobacterium bovis bacille Calmette-Guérin infection in the CNS suppresses experimental autoimmune encephalomyelitis and Th17 responses in an IFN-gamma-independent manner. J Immunol. 2008;181:6201–12. doi:10.4049/jimmunol.181.9.6201.
   PubMed Web of Science ®Google Scholar
• Laćan G, Dang H, Middleton B, Horwitz MA, Tian J, Melega WP, Kaufman DL. Bacillus Calmette-Guerin vaccine-mediated neuroprotection is associated with regulatory T-cell induction in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. J Neurosci Res. 2013;91:1292–302. doi:10.1002/jnr.v91.10.
   PubMed Web of Science ®Google Scholar
• Sewell DL, Reinke EK, Co DO, Hogan LH, Fritz RB, Sandor M, Fabry Z. Infection with Mycobacterium bovis BCG diverts traffic of myelin oligodendroglial glycoprotein autoantigen-specific T cells away from the central nervous system and ameliorates experimental autoimmune encephalomyelitis. Clin Diagn Lab Immunol. 2003;10(4):564–72. doi:10.1128/cdli.10.4.564-572.2003.
   PubMedGoogle Scholar
• Paolillo A, Buzzi MG, Giugni E, Sabatini U, Bastianello S, Pozzilli C, Salvetti M, Ristori G. The effect of bacille Calmette-Guérin on the evolution of new enhancing lesions to hypointense T1 lesions in relapsing remitting MS. J Neurol. 2003;250:247–48. doi:10.1007/s00415-003-0967-6.
   PubMed Web of Science ®Google Scholar
• Ristori G, Buzzi MG, Sabatini U, Giugni E, Bastianello S, Viselli F, Buttinelli C, Ruggieri S, Colonnese C, Pozzilli C, et al. Use of bacille Calmette-Guèrin (BCG) in multiple sclerosis. Neurology. 1999;53:1588–89. doi:10.1212/WNL.53.7.1588.
   PubMed Web of Science ®Google Scholar
• Ristori G, Romano S, Cannoni S, Visconti A, Tinelli E, Mendozzi L, Cecconi P, Lanzillo R, Quaratelli M, Buttorelli C, et al. Effects of bacille Calmette-Guerin after the first demyelinating event in the CNS. Neurology. 2014;82:41–48. doi:10.1212/01.wnl.0000438216.93319.ab.
   PubMed Web of Science ®Google Scholar
• Bourdette D, Naismith RT. BCG vaccine for clinically isolated syndrome and MS: infections and protective immunity. Neurology. 2014;82:15–16. Epub 2013 Dec 4. doi:10.1212/01.wnl.0000438232.40847.c3.
   PubMed Web of Science ®Google Scholar
• Lippens C, Garnier L, Guyonvarc’h PM, Santiago-Raber ML, Hugues S. Extended freeze-dried BCG instructed pDCs induce suppressive tregs and dampen EAE. Front Immunol. 2018;9:2777. doi:10.3389/fimmu.2018.02777.
   PubMed Web of Science ®Google Scholar
• Faustman DL, Wang L, Okubo Y, Burger D, Ban L, Man G, Zheng H, Schoenfeld D, Pompei R, Avruch J, et al. Proof-of-concept, randomized, controlled clinical trial of bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS One. 2012;7:e41756. doi:10.1371/journal.pone.0041756.
   PubMed Web of Science ®Google Scholar
• Faustman DL. TNF, TNF inducers, and TNFR2 agonists: A new path to type 1 diabetes treatment. Diabetes Metab Res Rev. 2018;34. Epub 2017 Sep 29. doi:10.1002/dmrr.2941.
   PubMed Web of Science ®Google Scholar
• Stienstra R, Netea MG. Firing up glycolysis: BCG vaccination effects on type 1 diabetes mellitus. Trends Endocrinol Metab. 2018 Oct. pii: S1043–2760(18)30169–3. doi:10.1016/j.tem.2018.10.001.
   Web of Science ®Google Scholar
• Kühtreiber WM, Tran L, Kim T, Dybala M, Nguyen B, Plager S, Huang D, Janes S, Defusco A, Baum D, et al. Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations. NPJ Vaccines. 2018 21;3:23. doi:10.1038/s41541-018-0062-8.
   PubMed Web of Science ®Google Scholar
• Fenner A. BCG enriches Treg cells. Nat Rev Urol. 2018;15:591. doi:10.1038/s41585-018-0075-0.
   PubMed Web of Science ®Google Scholar
• Parkash O, Agrawal S, Madhan Kumar M. T regulatory cells: achilles’ heel of Mycobacterium tuberculosis infection? Immunol Res. 2015;62:386–98. doi:10.1007/s12026-015-8654-0.
   PubMed Web of Science ®Google Scholar
• Vetskova EK, Muhtarova MN, Avramov TI, Stefanova TR, Chalakov IJ, Nikolova MH. Immunomodulatory effects of BCG in patients with recurrent respiratory papillomatosis. Folia Med (Plovdiv). 2013;55:49–54. doi:10.2478/folmed-2013-0005.
   PubMedGoogle Scholar
• Derkay CS, Smith RJ, McClay J, van Burik JA, Wiatrak BJ, Arnold J, Berger B, Neefe JR. HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann Otol Rhinol Laryngol. 2005;114:730–37. doi:10.1177/000348940511400913.
   PubMed Web of Science ®Google Scholar
• Jaisinghani AK, Dey VK, Suresh MS, Saxena A. Bacillus calmette-guerin immunotherapy for recurrent multiple warts: an open-label uncontrolled study. Indian J Dermatol. 2019;64(2):164. doi:10.4103/ijd.IJD_558_16.
   PubMed Web of Science ®Google Scholar
• Kemp EB, Belshe RB, Hoft DF. Immune responses stimulated by percutaneous and intradermal bacille Calmette-Guérin. J Infect Dis. 1996;174:113–19. doi:10.1093/infdis/174.1.113.
   PubMed Web of Science ®Google Scholar
• Ravn P, Boesen H, Pedersen BK, Andersen P. Human T cell responses induced by vaccination with Mycobacterium bovis bacillus Calmette-Guérin. J Immunol. 1997;158:1949–55.
   PubMed Web of Science ®Google Scholar
• Trevenen CL, Pagtakhan RD. Disseminated tuberculoid lesions in infants following BCG vaccination. Can Med Assoc J. 1982;127:502–04.
   PubMed Web of Science ®Google Scholar
• Fox GJ, Orlova M, Schurr E. Tuberculosis in newborns: the Lessons of the “Lübeck Disaster” (1929–1933). PLoS Pathog. 2016;12(1):e1005271. doi:10.1371/journal.ppat.1005271.
   PubMed Web of Science ®Google Scholar
• von Reyn CF. Routine childhood bacille Calmette Guérin immunization and HIV infection. Clin Infect Dis. 2006;42:559–61. doi:10.1086/499959.
   PubMed Web of Science ®Google Scholar
• Hesseling AC, Rabie H, Marais BJ, Manders M, Lips M, Schaaf HS, Gie RP, Cotton MF, van Helden PD, Warren RM, et al. Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis. 2006;42:548–58. Epub 2006 Jan 11. doi:10.1086/499953.
   PubMed Web of Science ®Google Scholar
• Derrick SC. Trained Immunity and Susceptibility to HIV. Clin Vaccine Immunol. 2017 5;24(1):pii: e00509–16. doi:10.1128/CVI.00509-16.
   PubMedGoogle Scholar
• Jensen K, Dela Pena-Ponce MG, Piatak M Jr, Shoemaker R, Oswald K, Jacobs WR Jr, Fennelly G, Lucero G, Mollan KR, Hudgens MG, et al. Balancing trained immunity with persistent immune activation and the risk of simian immunodeficiency virus infection in infant macaques vaccinated with attenuated mycobacterium tuberculosis or mycobacterium bovis BCG vaccine. Clin Vaccine Immunol. 2017;24(1):pii: e00360–16. doi:10.1128/CVI.00360-16.
   Google Scholar
• Thayil SM, Ho YC, Bollinger RC, Blankson JN, Siliciano RF, Karakousis PC, Page KR. Mycobacterium tuberculosis complex enhances susceptibility of CD4 T cells to HIVthrough a TLR2-mediated pathway. PLoS One. 2012;7:e41093. Epub 2012 Jul 23. doi:10.1371/journal.pone.0041093.
   PubMedGoogle Scholar
• Puthanakit T, Oberdorfer P, Punjaisee S, Wannarit P, Sirisanthana T, Sirisanthana V. Immune reconstitution syndrome due to bacillus Calmette-Guérin after initiation of antiretroviral therapy in children with HIV infection. Clin Infect Dis. 2005;41:1049–52. Epub 2005 Aug 30. doi:10.1086/433177.
   PubMed Web of Science ®Google Scholar
• Norouzi S, Aghamohammadi A, Mamishi S, Rosenzweig SD, Rezaei N. Bacillus Calmette-Guérin (BCG) complications associated with primary immunodeficiency diseases. J Infect. 2012;64:543–54. doi:10.1016/j.jinf.2012.03.012.
   PubMed Web of Science ®Google Scholar
• Marciano BE, Huang CY, Joshi G, Rezaei N, Carvalho BC, Allwood Z, Ikinciogullari A, Reda SM, Gennery A, Thon V, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol. 2014;133:1134–41. doi:10.1016/j.jaci.2014.02.028.
   PubMed Web of Science ®Google Scholar
• Conti F, Lugo-Reyes SO, Blancas Galicia L, He J, Aksu G, Borges de Oliveira E Jr, Deswarte C, Hubeau M, Karaca N, de Suremain M, et al. Mycobacterial disease in patients with chronic granulomatous disease: A retrospective analysis of 71 cases. J Allergy Clin Immunol. 2016;138:241–48. doi:10.1016/j.jaci.2015.11.041.
   PubMed Web of Science ®Google Scholar
• Bustamante J, Aksu G, Vogt G, de Beaucoudrey L, Genel F, Chapgier A, Filipe-Santos O, Feinberg J, Emile JF, Kutukculer N, et al. BCG-osis and tuberculosis in a child with chronic granulomatous disease. J Allergy Clin Immunol. 2007;120:32–38. doi:10.1016/j.jaci.2007.04.034.
   PubMed Web of Science ®Google Scholar
• Lin CJ, Wang SC, Ku CL, Kao JK, Chen M, Liu CS. Successful unrelated cord blood stem cell transplantation in an x-linked chronic granulomatous disease patient with disseminated BCG-induced Infection. Pediatr Neonatol. 2015;56:346–50. doi:10.1016/j.pedneo.2013.04.001.
   PubMed Web of Science ®Google Scholar
• Casanova JL, Blanche S, Emile JF, Jouanguy E, Lamhamedi S, Altare F, Stéphan JL, Bernaudin F, Bordigoni P, Turck D, et al. Idiopathic disseminated bacillus Calmette-Guérin infection: a French national retrospective study. Pediatrics. 1996;98(4 Pt 1):774–78.
   PubMed Web of Science ®Google Scholar
• Jouanguy E, Altare F, Lamhamedi S, Revy P, Emile JF, Newport M, Levin M, Blanche S, Seboun E, Fischer A, et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guérin infection. N Engl J Med. 1996;335:1956–61. doi:10.1056/NEJM199612263352604.
   PubMed Web of Science ®Google Scholar
• Rosain J, Kong XF, Martinez-Barricarte R, Oleaga-Quintas C, Ramirez-Alejo N, Markle J, Okada S, Boisson-Dupuis S, Casanova JL, Bustamante J. Mendelian susceptibility to mycobacterial disease: 2014–2018 update. Immunol Cell Biol. 2019;97:360–367.
   Google Scholar
• Rosenzweig SD. Old vaccines, new diseases: when BCG meets SPPL2a. Nat Immunol. 2018;19:906–07. doi:10.1038/s41590-018-0193-0.
   PubMed Web of Science ®Google Scholar
• Fieschi C, Dupuis S, Catherinot E, Feinberg J, Bustamante J, Breiman A, Altare F, Baretto R, Le Deist F, Kayal S, et al. Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications. J Exp Med. 2003;197:527–35. doi:10.1084/jem.20021769.
   PubMed Web of Science ®Google Scholar
• Nunes-Santos CJ, Rosenzweig SD. Bacille Calmette-Guerin complications in newly described primary immunodeficiency diseases: 2010–2017. Front Immunol. 2018;9:1423. doi:10.3389/fimmu.2018.01423.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Aron-Maor A, Tanai A, Ehrenfeld M. Bcg and autoimmunity: another two-edged sword. J Autoimmun. 2001;16:235–40. doi:10.1006/jaut.2000.0494.
   PubMed Web of Science ®Google Scholar
• Tinazzi E, Ficarra V, Simeoni S, Artibani W, Lunardi C. Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review. Rheumatol Int. 2006;26:481–88. doi:10.1007/s00296-005-0059-2.
   PubMed Web of Science ®Google Scholar
• Ng KL, Chua CB. Reiter’s syndrome postintravesical Bacillus Calmette-Guérin instillations. Asian J Surg. 2017;40:163–65. doi:10.1016/j.asjsur.2014.01.016.
   PubMed Web of Science ®Google Scholar
• van Eden W, Holoshitz J, Nevo Z, Frenkel A, Klajman A, Cohen IR. Arthritis induced by a T-lymphocyte clone that responds to Mycobacterium tuberculosis and to cartilage proteoglycans. Proc Natl Acad Sci U S A. 1985;82:5117–20. doi:10.1073/pnas.82.15.5117.
   PubMed Web of Science ®Google Scholar
• Hirayama T, Matsumoto K, Tsuboi T, Fujita T, Satoh T, Iwamura M, Ao T, Baba S. Anaphylactoid purpura after intravesical therapy using bacillus Calmette-Guerin for superficial bladder cancer. Hinyokika Kiyo. 2008;54:127–29. Article in Japanese.
   PubMedGoogle Scholar
• Tsukada H, Miyakawa H. Henoch schönlein purpura nephritis associated with intravesical Bacillus Calmette-Guerin (BCG) therapy. Intern Med. 2017;56:541–544.oi. doi:10.2169/internalmedicine.56.7494.
   PubMed Web of Science ®Google Scholar
• Nan DN, Fernández-Ayala M, García-Ibarbia C, Gutiérrez-Santiago M, Hernández JL. Henoch-schönlein purpura after intravesical administration of bacillus Calmette-Guérin. Scand J Infect Dis. 2005;37:613–15. doi:10.1080/00365540510035300.
   PubMed Web of Science ®Google Scholar
• Webb K, Venkatesan P. Guillain Barré syndrome associated with bladder instillation of bacille Calmette Guérin (BCG). JMM Case Rep. 2018;5(8):e005164. doi:10.1099/jmmcr.0.005164.
   PubMedGoogle Scholar
• Engleman EG, Sonnenfeld G, Dauphinee M, Greenspan JS, Talal N, McDevitt HO, Merigan TC. Treatment of NZB/NZW F1 hybrid mice with Mycobacterium bovis strain BCG or type II interferon preparations accelerates autoimmune disease. Arthritis Rheum. 1981;24:1396–402. doi:10.1002/(ISSN)1529-0131.
   PubMed Web of Science ®Google Scholar
• Spratt A, Key T, Vivian AJ. Chronic anterior uveitis following bacille Calmette-Guérin vaccination: molecular mimicry in action? J Pediatr Ophthalmol Strabismus. 2008;45:252–53. doi:10.3928/01913913-20080701-15.
   PubMed Web of Science ®Google Scholar
• Parent ME, Richer M, Liang P. The first case of bacillus Calmette-Guérin-induced small-vessel central nervous system vasculitis. Clin Rheumatol. 2018 May 9. Epub ahead of print. doi:10.1007/s10067-018-4136-9.
   PubMed Web of Science ®Google Scholar
• Donaldson RC, Canaan SA Jr, McLean RB, Ackerman LV. Uveitis and vitiligo associated with BCG treatment for malignant melanoma. Surgery. 1974;76:771–78.
   PubMed Web of Science ®Google Scholar
• Kothari SS. Aetiopathogenesis of Takayasu’s arteritis and BCG vaccination: the missing link? Med Hypotheses. 1995;45:227–30. doi:10.1016/0306-9877(95)90109-4.
   PubMed Web of Science ®Google Scholar
• Pasma H, Honkila M, Pokka T, Renko M, Salo E, Tapiainen T. Epidemiology of Kawasaki disease before and after universal bacille Calmette-Guérin vaccination program was discontinued. Acta Paediatr. Sep 13 2019. doi:10.1111/apa.15012.
   PubMed Web of Science ®Google Scholar
• Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, Rodrigues LC, Smith PG, Lipman M, Whiting PF, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58:470–80. doi:10.1093/cid/cit790.
   PubMed Web of Science ®Google Scholar
• Hatherill M, Geldenhuys H, Pienaar B, Suliman S, Chheng P, Debanne SM, Hoft DF, Boom WH, Hanekom WA, Johnson JL, et al. Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults. Vaccine. 2014;32:3982–88. doi:10.1016/j.vaccine.2014.04.084.
   PubMed Web of Science ®Google Scholar
• Suliman S, Geldenhuys H, Johnson JL, Hughes JE, Smit E, Murphy M, Toefy A, Lerumo L, Hopley C, Pienaar B, et al. Bacillus Calmette-Guérin (BCG) revaccination of adults with latent mycobacterium tuberculosis infection induces long-lived BCG-reactive NK cell responses. J Immunol. 2016;197:1100–10. doi:10.4049/jimmunol.1501996.
   PubMed Web of Science ®Google Scholar
• Dye C. Making wider use of the world’s most widely used vaccine: bacille Calmette-Guerin revaccination reconsidered. J R Soc Interface. 2013;10:20130365. doi:10.1098/rsif.2013.0365.
   PubMed Web of Science ®Google Scholar
• Nemes E, Geldenhuys H, Rozot V, Rutkowski KT, Ratangee F, Bilek N, Mabwe S, Makhethe L, Erasmus M, Toefy A, et al. C-040–404 study team. Prevention of M. tuberculosis Infection with H4: IC31Vaccine or BCG revaccination. N Engl J Med. 2018;379:138–49. doi:10.1056/NEJMoa1714021.
   PubMed Web of Science ®Google Scholar
• World Health Organization. BCG vaccine: WHO position paper, February 2018 - recommendations. Vaccine. 2018;36:3408–10. doi:10.1016/j.vaccine.2018.03.009.
   PubMed Web of Science ®Google Scholar
• Bloom BR. New promise for vaccines against tuberculosis. N Engl J Med. 2018;379:1672–74. doi:10.1056/NEJMe1812483.
   PubMed Web of Science ®Google Scholar
• Méndez-Samperio P. Development of tuberculosis vaccines in clinical trials: current status. Scand J Immunol. 2018;88:e12710. doi:10.1111/sji.12710.
   PubMed Web of Science ®Google Scholar
• Dijkman K, Sombroek CC, Vervenne RAW, Hofman SO, Boot C, Remarque EJ, Kocken CHM, Ottenhoff THM, Kondova I, Khayum MA, et al. Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques. Nat Med. 2019 Jan 21. Epub ahead of print. doi:10.1038/s41591-018-0319-9.
   PubMed Web of Science ®Google Scholar
• Abdallah AM, Behr MA. Evolution and strain variation in BCG. Adv Exp Med Biol. 2017;1019:155–69. doi:10.1007/978-3-319-64371-7_8.
   PubMedGoogle Scholar
• Krajewski W, Matuszewski M, Poletajew S, Grzegrzółka J, Zdrojowy R, Kołodziej A. Are there differences in toxicity and efficacy between various bacillus calmette-guerin strains in bladder cancer patients? Analysis of 844 patients. Urol Int. 2018;101:277–84. doi:10.1159/000492722.
   PubMed Web of Science ®Google Scholar